Background: Information about the long-term tolerability of tafasitamab is still limited.
Methods: 5 of 92 patients treated within a phase IIa study of single-agent tafasitamab in relapsed or refractory B NHL were followed for up to five years or longer for long-term tolerability.
Results: Treatment was very well tolerated in an outpatient setting with no hospitalizations needed and mild and tolerable adverse events that occurred mostly within the first two years of treatment.
Conclusions: Given the excellent tolerability and efficacy of tafasitamab this agent can be used to induce remission in relapsed or refractory lymphoma either alone or in combination with chemotherapy.
Keywords: B cell malignancy; Cancer; Immunotherapy; Monoclonal antibody; Non-Hodgkin lymphoma.
Copyright © 2021. Published by Elsevier Inc.